CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化细菌辅助 CAR-T 细胞治疗在胃肠道肿瘤中的前景
英文原题：Prospects of engineered bacteria-assisted CAR T Cell therapy in gastrointestinal cancers.
查看英文原题
Prospects of engineered bacteria-assisted CAR T Cell therapy in gastrointestinal cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胃肠道癌症发病率和死亡率均高，是全球重大健康挑战。近年来，CAR-T 细胞疗法作为一种有前景的免疫治疗方法，已显示良好的临床结局。然而，传统CAR-T 疗法用于胃肠道癌症仍面临诸多挑战，包括免疫抑制性肿瘤微环境及抗肿瘤疗效有限。工程化细菌可通过调节肿瘤微环境、增强免疫应答，为改善CAR-T 细胞疗法提供新策略，并可能进一步提高治疗结局。本综述总结工程化细菌辅助CAR-T 疗法治疗胃肠道癌症的研究进展，探讨其作用机制、临床应用及未来发展方向。
展开英文摘要原文
The high incidence and mortality rates associated with gastrointestinal cancers represent a significant global health challenge. In recent years, CAR T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating favorable clinical outcomes.
However, the application of traditional CAR T cell therapy in gastrointestinal cancers faces numerous challenges, including the suppressive tumor microenvironment and limitations in anti-tumor efficacy. The application of engineered bacteria offers a novel strategy to enhance CAR T cell therapy by modulating the tumor microenvironment and boosting immune responses, potentially leading to improved therapeutic outcomes.
This review synthesizes the current research advancements related to engineered bacteria-assisted CAR T cell therapy in gastrointestinal cancers, exploring its underlying mechanisms, clinical applications, and future developmental directions.
论文信息
- 作者
- Zhang Q、Song X、Liu J、Zhou X
- 第一作者单位
- Reproductive Medicine, Weifang People's Hospital, Weifang, Shandong, China.China
- 通讯作者单位
- Hospital Preparation Center, Weifang People's Hospital, Weifang, Shandong, China.China
- 文献类型
- 综述
- 期刊
- Oncology reviews2025
- 原文标识
- PubMed 40297102 · DOI 10.3389/or.2025.1581856
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →